Viralytics Completes Phase I Melanoma Trial
The secondary objective of the trial also monitored the injected tumour and other distant tumours for signs of Cavatak activity against actively progressing metastatic melanoma. Injected tumours of
The US Food and Drug Administration (FDA) is set to review Kowa Pharmaceuticals America’s new drug application (NDA) for K-911, an investigational once-daily eye drop aimed at reducing intraocular pressure (IOP) in open-angle glaucoma (OAG) or ocular hypertension (OHT) patients.